$1.69 Billion is the total value of Sofinnova Investments, Inc.'s 53 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 47.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ASND | Buy | Ascendis Pharma A/Ssponsored adr | $107,572,104 | +108.4% | 880,800 | +76.2% | 6.38% | +112.6% |
| SNY | Buy | Sanofi SAsponsored adr | $95,187,954 | +98.0% | 1,965,475 | +55.4% | 5.65% | +101.9% |
| MRK | Buy | Merck & Co Inc | $66,942,348 | +33.2% | 603,356 | +3.4% | 3.97% | +35.8% |
| HZNP | New | Horizon Therapeutics PLC | $47,019,087 | – | 413,173 | +100.0% | 2.79% | – |
| VRTX | New | Vertex Pharmaceuticals Inc | $45,335,283 | – | 156,989 | +100.0% | 2.69% | – |
| BMRN | Buy | Biomarin Pharmaceutical Inc | $40,841,604 | +63.5% | 394,643 | +33.9% | 2.42% | +66.7% |
| RETA | Buy | Reata Pharmaceuticals Inccl a | $37,687,182 | +83.2% | 992,029 | +21.2% | 2.24% | +86.8% |
| SRPT | Buy | Sarepta Therapeutics Inc | $32,130,009 | +105.5% | 247,955 | +75.3% | 1.91% | +109.6% |
| CTIC | Buy | CTI Biopharma Corp | $27,685,227 | +31.7% | 4,606,527 | +27.5% | 1.64% | +34.3% |
| INBX | Buy | Inhibrx Inc | $27,354,909 | +238.5% | 1,110,183 | +146.6% | 1.62% | +245.3% |
| ALNY | New | Alnylam Pharmaceuticals Inccall | $23,765,000 | – | 100,000 | +100.0% | 1.41% | – |
| CYTK | Buy | Cytokinetics Inc | $23,319,173 | +50.1% | 508,930 | +58.7% | 1.38% | +53.1% |
| KDNY | Buy | Chinook Therapeutics Inc | $21,129,226 | +273.3% | 806,459 | +180.1% | 1.25% | +281.2% |
| ZNTL | Buy | Zentalis Pharmaceuticals Inc | $20,221,466 | +60.0% | 1,004,045 | +72.1% | 1.20% | +63.3% |
| RXDX | Buy | Prometheus Biosciences Inc | $19,419,950 | +135.5% | 176,545 | +26.3% | 1.15% | +140.0% |
| SNDX | Buy | Syndax Pharmaceuticals Inc | $17,893,233 | +41.8% | 703,074 | +33.9% | 1.06% | +44.7% |
| ALGN | New | Align Technology Inc | $17,525,790 | – | 83,100 | +100.0% | 1.04% | – |
| IMTX | Buy | Immatics NV | $17,426,759 | +227.3% | 2,000,776 | +275.7% | 1.03% | +233.5% |
| ALNY | New | Alnylam Pharmaceuticals Inc | $13,414,867 | – | 56,448 | +100.0% | 0.80% | – |
| TVTX | Buy | Travere Therapeutics Inc | $12,160,976 | +25.0% | 578,268 | +46.5% | 0.72% | +27.6% |
| IMGN | Buy | ImmunoGen Inc | $8,363,324 | +248.3% | 1,686,154 | +235.6% | 0.50% | +254.3% |
| KURA | New | Kura Oncology Inc | $7,366,092 | – | 593,561 | +100.0% | 0.44% | – |
| AGEN | Buy | Agenus Inc | $6,945,737 | +39.0% | 2,894,057 | +18.7% | 0.41% | +41.6% |
| GERN | Buy | Geron Corpcall | $5,733,222 | +128.5% | 2,369,100 | +121.0% | 0.34% | +132.9% |
| CYTK | New | Cytokinetics Inccall | $4,582,000 | – | 100,000 | +100.0% | 0.27% | – |
| GERN | Buy | Geron Corp | $3,532,205 | +26.9% | 1,459,589 | +22.7% | 0.21% | +29.6% |
| AGEN | New | Agenus Inccall | $3,040,800 | – | 1,267,000 | +100.0% | 0.18% | – |
| CTIC | New | CTI Biopharma Corpcall | $2,464,100 | – | 410,000 | +100.0% | 0.15% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Natera, Inc. | 23 | Q3 2023 | 20.5% |
| Ascendis Pharma A/S | 23 | Q3 2023 | 27.9% |
| NuCana plc | 23 | Q3 2023 | 15.2% |
| Synlogic Inc. (fmrly Mirna) | 22 | Q2 2023 | 0.9% |
| Y-mAbs Therapeutics, Inc. | 21 | Q3 2023 | 6.5% |
| ObsEva SA | 20 | Q4 2022 | 11.0% |
| Nucana PLC | 19 | Q3 2023 | 9.7% |
| SYNDAX PHARMACEUTICALS INC | 19 | Q3 2023 | 2.2% |
| PDS Biotechnology Corporation | 19 | Q3 2023 | 0.1% |
| Karuna Therapeutics, Inc. | 18 | Q3 2023 | 27.1% |
View Sofinnova Investments, Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| OTONOMY, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Sofinnova Investments, Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
View Sofinnova Investments, Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.